natgillin/translations-raw huggingface dataset:
The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis ( 10% BSA involvement and PASI  12 or  10) who were candidates for systemic therapy or phototherapy in randomised, double-blind studies. 
Varnost in učinkovitost zdravila Humira so raziskali v randomiziranih, dvojno slepih študijah pri odraslih bolnikih s kronično psoriazo v plakih (zajete ≥ 10 % telesne površine ter indeksom obsežnosti in izrazitosti psoriaze PASI ≥ 12 ali ≥ 10), ki so bili kandidati za sistemsko zdravljenje ali fototerapijo.
Humira is used to treat moderate to severe Crohn's disease in children and adolescents aged 6 to 17 years. 
Zdravilo Humira je namenjeno za zdravljenje Crohnove bolezni pri otrocih in mladostnikih, starih 6 do 17 let.
• If you have an infection, including long-term or localized infection (for example, leg ulcer) consult your doctor before starting Humira. 
• Če imate kakšno okužbo, vključno z dolgotrajno ali omejeno okužbo (npr. razjedo na nogi), se pred uporabo zdravila Humira posvetujte s svojim zdravnikom.
Humira is also used to treat severe plaque psoriasis in children and adolescents aged 4 to 17 years for whom topical therapy and phototherapies have either not worked very well or are not suitable. 
Zdravilo Humira se uporablja tudi za zdravljenje hude luskavice v plakih pri otrocih in mladostnikih, starih od 4 do 17 let, pri katerih lokalno zdravljenje in fototerapija nista dovolj dobro delovala ali pa nista primerna.
• The following instructions explain how to give yourself a subcutaneous injection of Humira using the pre-filled syringe. 
• Naslednja navodila pojasnjujejo, kako si subkutano injicirate zdravilo Humira z napolnjeno injekcijsko brizgo.
PGA: Clear/minimal a, b p < 0.001 Humira vs. placebo p < 0.001 Humira vs. methotrexate p < 0.01 Humira vs. placebo p < 0.05 Humira vs. methotrexate 
79 (73,1) a, b a p < 0,001 zdravilo Humira v primerjavi s placebom b p < 0,001 zdravilo Humira v primerjavi z metotreksatom c p < 0,01 zdravilo Humira v primerjavi s placebom d p < 0,05 zdravilo Humira v primerjavi z metotreksatom
Humira 40 mg solution for injection in pre-filled syringe EU/1/03/256/012 
Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/03/256/012
Therefore, the combination of adalimumab and anakinra is not recommended. 
Zato kombinacija adalimumaba in anakinre ni priporočena (glejte poglavje 4.5).
Humira has not been studied in these patient populations. 
Zdravilo Humira pri teh populacijah bolnikov še ni bilo preskušeno, zato priporočil za odmerjanje ni mogoče dati.
Humira is used to treat severe chronic plaque psoriasis in children and adolescents aged 4 to 17 years for whom topical therapy and phototherapies have either not worked very well or are not suitable. 
Zdravilo Humira se uporablja za zdravljenje hude kronične luskavice v plakih pri otrocih in mladostnikih, starih od 4 do 17 let, pri katerih lokalno zdravljenje in fototerapija nista dovolj dobro delovala ali pa nista primerna.
• 1 pre-filled syringe (0.8 ml sterile solution) with 1 alcohol pad in a blister. 
• 1 napolnjena injekcijska brizga (0,8 ml sterilne raztopine) z 1 alkoholnim zložencem v pretisnem omotu.
Figure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis Study 
Slika 3: Kaplan-Meier-jeve krivulje povzemajo čas do neuspeha zdravljenja v študiji uveitisa pri pediatričnih bolnikih
• arm or leg weakness 
• šibkost rok ali nog
First dose of 160 mg (two 80 mg injections in one day or one 80 mg injection per day for two consecutive days), followed by 80 mg (one 80 mg injection) two weeks later. 
Prvi odmerek je 160 mg (dve 80 mg injekciji v enem dnevu ali ena 80 mg injekcija na dan dva zaporedna dneva), čemur sledi 80 mg (ena 80 mg injekcija) dva tedna kasneje.
3 pre-filled pens 4 alcohol pads 
3 napolnjeni injekcijski peresniki 4 alkoholni zloženci
Humira 40 mg solution for injection in pre-filled syringe EU/1/03/256/002 
Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/03/256/002
• 1 pre-filled syringe (0.4 ml sterile solution) with 1 alcohol pad in a blister. 
• 1 napolnjena injekcijska brizga (0,4 ml sterilne raztopine) z 1 alkoholnim zložencem v pretisnem omotu.
• Advise your doctor if your child has a history of recurrent infections or other conditions that increase the risk of infections. 
• Zdravniku povejte, če je vaš otrok imel v preteklosti ponavljajoče se okužbe ali druge bolezni, ki zvečujejo tveganje za okužbe.
Humira is used to treat severe plaque psoriasis in children and adolescents aged 4 to 17 years in whom topical therapy and phototherapies have either not worked very well or are not suitable. 
Zdravilo Humira se uporablja za zdravljenje hude luskavice v plakih pri otrocih in mladostnikih, starih od 4 do 17 let, pri katerih lokalno zdravljenje in fototerapija nista dovolj dobro delovala ali pa nista primerna.
If a faster response is required, your child's doctor may prescribe a first dose of 160 mg, followed by 80 mg two weeks later. 
Če je potreben hitrejši odziv, lahko zdravnik vašemu otroku predpiše začetni odmerek 160 mg
Elevated liver enzymes 
zelo pogosti zvišani jetrni encimi
• Advise your doctor if your child resides or travels in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are endemic. 
• Zdravniku morate povedati, če vaš otrok živi na območju ali potujete v predele, kjer so endemične glivične okužbe, npr. histoplazmoza, kokcidioidomikoza ali blastomikoza.
RA Study III a** 
Študija revmatoidnega artritisa Ia**
One 0.8 ml pre-filled syringe contains 80 mg adalimumab. 
En 0,8 ml napolnjen injekcijski peresnik vsebuje 80 mg adalimumaba.
The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer). 
Injekcijska igla znotraj peresnika je narejena iz stekla tipa I z batno zaporko (bromobutilni kavčuk) in igle z varovalnim pokrovčkom (termoplastični elastomer).
Hepatosplenic T-cell lymphoma Merkel cell carcinoma (neuroendocrine 
hepatosplenični T-celični limfom1)
Check the expiry date on the pre-filled pen label (EXP:) Do not use the product if the date has passed the month and year shown. 
Preverite datum izteka roka uporabnosti na peresniku (Uporabno do).
Children, adolescents and adults from 6 years of age weighing 30 kg or more 
Otroci, mladostniki in odrasli od 6. leta starosti, ki tehtajo 30 kg ali več
In study UC-I, 390 TNF-antagonist naïve patients were randomised to receive either placebo at Weeks 0 and 2, 160 mg Humira at Week 0 followed by 80 mg at Week 2, or 80 mg Humira at Week 0 followed by 40 mg at Week 2. 
V študiji UC-I so 390 bolnikov, ki še niso prejemali antagonista TNF, randomizirali bodisi na placebo 0. in 2. teden, na zdravilo Humira 0. teden in 80 mg 2. teden, ali na 80 mg 0. teden in 40 mg 2. teden.
• pulmonary fibrosis (scarring of the lung) 
• pljučna fibroza (brazgotinjenje pljuč)
If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your doctor or pharmacist and tell them that your child has taken more. 
Če pomotoma injicirate zdravilo Humira pogosteje, kot vam je naročil zdravnik, se morate posvetovati z zdravnikom ali farmacevtom in jima povedati, da je vaš otrok uporabil večji odmerek.
Table 12 Radiographic Mean Changes at Week 52 in RA Study V 
Preglednica 12: Povprečne rentgenografske spremembe po 52 tednih študije revmatoidnega artritisa V
CD study I and CD study II induction of remission and response rates are presented in Table 20. 
Indukcijo remisije in deleže odziva v študiji pri Crohnovi bolezni I in študiji pri Crohnovi bolezni II prikazuje preglednica 20.
Table 10 ACR Responses in RA Study V (percent of patients) 
Pregledica 10: Odzivi ACR v študiji revmatoidnega artritisa V (odstotek bolnikov)
First dose of 160 mg (two 80 mg injections in one day or one 80 mg injection per day for two consecutive days), followed by an 80 mg dose (one 80 mg injection) two weeks later. 
Prvi odmerek je 160 mg (dve 80 mg injekciji v enem dnevu ali ena 80 mg injekcija na dan dva zaporedna dneva), čemur sledi 80 mg odmerek (ena 80 mg injekcija) dva tedna kasneje.
Humira 80 mg solution for injection in pre-filled syringe Each 0.8 ml single dose pre-filled syringe contains 80 mg of adalimumab. 
Humira 80 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Ena 0,8 ml napolnjena injekcijska brizga z enim odmerkom vsebuje 80 mg adalimumaba.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
PODATKI NA ZUNANJI OVOJNINI NOTRANJA ŠKATLA
When needed (for example when you are travelling), a single Humira pre-filled syringe may be stored at room temperature (up to 25°C) for a maximum period of 14 days - be sure to protect it from light. 
Če je potrebno (na primer kadar potujete), lahko posamezno napolnjeno injekcijsko brizgo zdravila Humira hranite pri sobni temperaturi (do 25 ºC) za največ 14 dni - zagotovite, da bo zaščitena pred svetlobo.
In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of patients receiving placebo or active control. 
12,9 % bolnikov, ki so dobivali zdravilo Humira, in 7,2 % bolnikov, ki so dobivali placebo ali kontrolno učinkovino.
• Tell your doctor if you have had infections which keep coming back or other conditions that increase the risk of infections. 
• Zdravniku povejte, če ste imeli v preteklosti ponavljajoče se okužbe ali druga stanja, ki povečajo tveganje za okužbe.
Enrolled patients were either current users of Humira 40 mg/0.8 ml and rated their average injection site pain as at least 3 cm (on a 0-10 cm VAS) or were biologic-naïve subjects who were starting Humira 40 mg/0.8 ml. 
Humira 40 mg/0,8 ml in so ocenili njihovo povprečno bolečino na mestu injiciranja kot vsaj 3 cm (na vizualni analogni lestvici od 0 do 10 cm VAS - Visual Analog Scale) ali pa še niso prejemali terapije z biološkimi zdravili in so začeli z zdravljenjem z zdravilom Humira 40 mg/0,8 ml. Bolniki so bili randomizirani tako, da so prejeli enkraten odmerek zdravila Humira 40 mg/0,8 ml ali Humira 40 mg/0,4 ml, ki mu je pri naslednjem odmerku sledila ena injekcija nasprotnega zdravljenja.
In patients who develop HBV 
Bolniki, ki so že dobivali infliksimab
Clinical Response Clinical Remission Mucosal Healing 
Klinična remisija Klinični odziv
If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your doctor or pharmacist and tell them that you have taken more. 
Če pomotoma injicirate zdravilo Humira pogosteje, kot vam je naročil zdravnik ali farmacevt, se morate posvetovati z zdravnikom ali farmacevtom in jima povedati, da ste uporabili večji odmerek.
Children, adolescents and adults from 6 years of age weighing 40 kg or more 
Otroci, mladostniki in odrasli od 6. leta starosti, ki tehtajo 40 kg ali več
• Advise your doctor if you reside or travel in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are endemic. 
• Zdravniku morate povedati, če živite na območju ali potujete v predele, kjer so endemične glivične okužbe, npr. histoplazmoza, kokcidioidomikoza ali blastomikoza.
The syringe or pen must be protected from light, and discarded if not used within the 14-day period. 
Brizga ali peresnik morata biti zaščitena pred svetlobo.
GI haemorrhage, dyspepsia, gastroesophageal reflux disease, sicca syndrome 
navzeja in bruhanje pogosti gastrointestinalna krvavitev, dispepsija, bolezen gastroezofagealnega refluksa Sjögrenov sindrom občasni redki pankreatitis, disfagija, edem obraza intestinalna perforacija1)
There is no relevant use of Humira in the paediatric population for the indications of ankylosing spondylitis and psoriatic arthritis. 
Psoriatični artritis in aksialni spondiloartritis, vključno z ankiloznim spondilitisom Uporaba zdravila Humira pri pediatrični populaciji za indikaciji ankilozni spodilitis in psoriatični artritis ni primerna.
Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis Study 
Slika 2: Kaplan-Meier-jeve krivulje povzemajo čas do neuspeha zdravljenja v študiji uveitisa pri pediatričnih bolnikih
urinary tract infections (including pyelonephritis), 
okužbe reproduktivnega trakta (vključno z vulvovaginalno mikotično okužbo), okužbe urinarnega trakta (vključno s pielonefritisom),
First dose of 80 mg (one 80 mg injection), followed by 40 mg two weeks later. 
80 mg (ena 80 mg injekcija) dva tedna kasneje.
• neurological infections (including viral meningitis); 
• nevrološke okužbe (vključno z virusnim meningitisom); • okužbe oči;
Humira 80 mg solution for injection in pre-filled syringe is supplied as a sterile solution of 80 mg adalimumab dissolved in 0.8 ml solution. 
Zdravilo Humira 80 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku je na voljo kot sterilna raztopina 80 mg adalimumaba, raztopljenega v 0,8 ml raztopine.
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with Humira versus patients receiving placebo (See Table 22). 
Klinični odziv Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali zdravilo Humira, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 22).
Again, SLOWLY pull the white plunger rod out to 0.1 ml beyond the prescribed dose, this is important to get the proper dose and important in order to prevent air bubbles or air gaps in the liquid medication. 
to je pomembno, da boste dobili pravilen odmerek in da boste preprečili zračne mehurčke ali zračne presledke v tekočem zdravilu.
If you develop a fever that does not go away, bruise or bleed very easily or look very pale, call your doctor right away. 
Če se pri vas pojavi zvišana telesna temperatura, ki ne mine, blage podplutbe ali zlahka zakrvavite ali pa ste zelo bledi, takoj pokličite svojega zdravnika.
Systemic infections (including sepsis, candidiasis and influenza), intestinal infections (including gastroenteritis viral), skin and soft tissue infections (including paronychia, cellulitis, impetigo, necrotising fasciitis and herpes zoster), ear infections, oral infections (including herpes simplex, oral herpes and tooth infections), reproductive tract infections (including vulvovaginal mycotic infection), 
črevesne okužbe (vključno z virusnim gastroenteritisom), okužbe kože in mehkih tkiv (vključno z zanohtnico, celulitisom, impetigom,
First dose of 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by 80 mg (two 40 mg injections in one day) two weeks later. 
Prvi odmerek je 160 mg (štiri 40 mg injekcije v enem dnevu ali dve 40 mg injekciji na dan dva zaporedna dneva), čemur sledi 80 mg (dve 40 mg injekciji v enem dnevu) dva tedna kasneje.
Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-antagonist therapy to prevent HBV reactivation are not available. 
Pri bolnikih, ki so pozitivni na okužbo s hepatitisom B, se priporoča posvetovanje z zdravnikom specialistom za zdravljenje okužb s hepatitisom B. Nosilce HBV, ki potrebujejo zdravljenje z zdravilom Humira, je treba ves čas zdravljenja in več mesecev po koncu zdravljenja natančno spremljati glede znakov in simptomov aktivne okužbe s HBV. O zdravljenju nosilcev HBV s protivirusno terapijo v kombinaciji z antagonistom TNF za preprečitev reaktivacije HBV ni zadostnih podatkov.
RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were  18 years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or have been intolerant to 10 mg of methotrexate every week. 
V študiji revmatoidnega artritisa III je bilo ocenjeno 619 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, ki se niso učinkovito odzvali na odmerke metotreksata od
Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving Humira. 
Pri bolnikih, zdravljenih z zdravilom Humira, so poročali o tuberkulozi, vključno z reaktivacijo in novimi pojavi tuberkuloze.
PASI 75 and PGA of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks). 
Po dodatnih 108 tednih odprtega zdravljenja (skupaj 160 tednov) sta bila pri teh bolnikih delež odziva PASI 75 74,7 % in delež odziva PGA "čisto" ali "minimalno" 59,0 %.
Humira 80 mg solution for injection in pre-filled pen EU/1/03/256/021 
Humira 80 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku EU/1/03/256/021
First dose of 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by an 80 mg dose (two 40 mg injections in one day) two weeks later. 
Prvi odmerek je 160 mg (štiri 40 mg injekcije v enem dnevu ali dve 40 mg injekciji na dan dva zaporedna dneva), čemur sledi 80 mg odmerek (dve 40 mg injekciji v enem dnevu) dva tedna kasneje.
In some rare cases, especially if you are taking other medicines that suppress the immune system, reactivation of HBV can be life-threatening. 
V redkih primerih, zlasti če uporabljate druga zdravila, ki zavirajo imunski sistem, je reaktivacija HBV
Humira 40 mg solution for injection in pre-filled pen EU/1/03/256/007 
Humira 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku EU/1/03/256/007
Humira 40 mg solution for injection in vials is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution. 
Zdravilo Humira 40 mg raztopina za injiciranje v vialah je na voljo kot sterilna raztopina 40 mg adalimumaba, raztopljenega v 0,8 ml raztopine.
Humira 40 mg solution for injection in pre-filled pen EU/1/03/256/016 
Humira 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku EU/1/03/256/016
Humira is used to treat moderate to severe chronic plaque psoriasis in adults. 
Zdravilo Humira se uporablja za zdravljenje zmerne do hude kronične luskavice pri odraslih.
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with Humira versus patients receiving placebo (See Table 29). 
Klinični odziv Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali zdravilo Humira, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 29).
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with Humira versus patients receiving placebo (See Table 19). 
Klinični odziv Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali zdravilo Humira, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 19).
• 1 pre-filled pen (0.4 ml sterile solution), with 2 alcohol pads in a blister. 
• 1 napolnjen injekcijski peresnik (0,4 ml sterilne raztopine) z 2 alkoholnima zložencema v pretisnem omotu.
One 0.4 ml pre-filled syringe contains 40 mg adalimumab. 
Ena 0,4 ml napolnjena injekcijska brizga vsebuje 40 mg adalimumaba.
Humira 20 mg solution for injection in pre-filled syringe adalimumab 
Humira 20 mg raztopina za injiciranje v napolnjeni injekcijski brizgi adalimumab
Non-infectious uveitis 
Neinfekcijski uveitis
b p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate combination therapy using the Mann-Whitney U test c p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy using the Mann-Whitney U test 
Celotna Sharpova ocena Ocena erozij Seštevek JSN a Vrednost p se nanaša na parno primerjavo monoterapije z metotreksatom in kombinirane terapije z zdravilom Humira/metotreksatom z Mann-Whitneyevim testom U b Vrednost p se nanaša na parno primerjavo monoterapije z zdravilom Humira in kombinirane terapije z zdravilom Humira/metotreksatom z Mann-Whitneyevim testom U c Vrednost p se nanaša na parno primerjavo monoterapije z zdravilom Humira in monoterapije z metotreksatom z Mann-Whitneyevim testom U.
All p-values are pairwise comparisons of proportions for Humira versus placebo * p < 0.001 
Vse vrednosti p so za parne primerjave deležev med zdravilom Humira in placebom.
• 1 pre-filled pen (0.8 ml sterile solution), with 2 alcohol pads in a blister. 
• 1 napolnjen injekcijski peresnik (0,8 ml sterilne raztopine) z 2 alkoholnima zložencema v pretisnem omotu.
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with Humira versus patients receiving placebo (See Table 24). 
Klinični odziv Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali zdravilo Humira, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 24).
ASAS Partial Remission BASDAI 
ASAS delno izboljšanje BASDAIb50
Solution for injection 1 pre-filled pen 2 alcohol pads 
raztopina za injiciranje 1 napolnjen injekcijski peresnik 2 alkoholna zloženca
• Check with your doctor before your child receives any vaccines. 
• Preden vaš otrok opravi kakršno koli cepljenje, se posvetujte z zdravnikom.
It is important that you tell your doctor if your child has symptoms of infections, for example, fever, wounds, feeling tired, dental problems. 
Pomembno je, da zdravniku poveste, če ima vaš otrok simptome okužb, npr. zvišano telesno temperaturo, rane, občutek utrujenosti ali težave z zobmi.
Intestinal perforation 
Avtoimuna obolenja
• fatty liver 
• zamaščenost jeter
In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was 160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg. At Week 4, patients were randomised 1:1 to either the Standard Dose (40/20 mg eow) or Low Dose (20/10 mg eow) maintenance treatment groups based on their body weight. 
Pediatrični bolniki z zmerno do hudo Crohnovo boleznijo so odvisno od njihove telesne mase (več ali manj od 40 kg) dobivali odprt začetni odmerek adalimumaba 160/80 mg v 0. tednu in 80/40 mg v
There is no relevant use of Humira in children aged less than 2 years in this indication. 
Uporaba zdravila Humira pri otrocih, mlajših od 2 let, za to indikacijo ni primerna.
• The following instructions explain how to give yourself a subcutaneous injection of Humira using the pre-filled pen. 
• Naslednja navodila pojasnjujejo, kako si subkutano injicirati zdravilo Humira z napolnjenim injekcijskim peresnikom.
In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. 
NP NP a Študija revmatoidnega artritisa I po 24 tednih, študija revmatoidnega artritisa II po 26 tednih in študija revmatoidnega artritisa III po 24 in 52 tednih b 40 mg zdravilo Humira vsak drugi teden c MTX = metotreksat **p < 0,01, zdravilo Humira v primerjavi s placebom; V študijah revmatoidnega artritisa I-IV so se v primerjavi s placebom po 24 oz. 26 tednih izboljšali vsi posamezni elementi meril odziva po ACR (število bolečih in oteklih sklepov, zdravnikova in bolnikova ocena aktivnosti bolezni in bolečin, vrednost indeksa invalidnosti (HAQ) in vrednost CRP
If your child develops a fever that does not go away, develops light bruises or bleeds very easily or looks very pale, call your doctor right away. 
Če vaš otrok dobi zvišano telesno temperaturo, ki ne mine, če se mu pojavljajo podplutbe, zlahka zakrvavi ali je zelo bled, se takoj posvetujte s svojim zdravnikom.
This will include a thorough medical evaluation including your child's medical history and appropriate screening tests (for example chest X-ray and a tuberculin test). 
To bo vključevalo natančno zdravniško oceno vključno s poizvedbo o zdravju vašega otroka v preteklosti in ustrezne preiskave (npr. rentgensko slikanje prsnega koša in tuberkulinski test).